Influence of Light Exposure on Cerebral MAO-A in Seasonal Affective Disorder and Healthy Controls Measured by PET

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

99 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-11-30

Study Completion Date

2017-04-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to assess differences in monoamine oxidase A (MAO-A) distribution in the brain between seasonal affective disorder patients and healthy controls using positron emission tomography. In addition the investigators aim to demonstrate the impact of light therapy on MAO-A distribution

In addition, a pilot study and a sub-study in healthy controls were performed

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigation of Seasonal Variations of Brain Structure and Connectivity in SAD

NCT03313674

Seasonal Affective Disorder Major Depressive Disorder Neuroimaging

COMPLETED NA

The Efficacy and Feasibility of Bright Light Therapy in Adolescents With Depressive Disorder

NCT06913309

Depressive Disorder, Major

NOT_YET_RECRUITING NA

Bright Light Therapy in Seasonal Affective Disorder (SAD)

NCT01293409

Seasonal Affective Disorder

COMPLETED NA

Low Intensity 'Blue Light' Treatment of Seasonal Affective Disorder

NCT01149135

Seasonal Affective Disorder

COMPLETED NA

Seasonal Affective Disorder and Visual Impairment

NCT03403959

Seasonal Affective Disorder Visual Impairment

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study aims to assess differences in monoamine oxidase A (MAO-A) distribution in the brain between seasonal affective disorder patients and healthy controls using positron emission tomography. In addition, the investigators aim to demonstrate the impact of light therapy on MAO-A distribution by investigating patients and controls in the winter before bright light therapy, in the winter after bright-light therapy, and in the summer. Bright light therapy will be placebo controlled, randomized, and double blinded.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Seasonal Affective Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Light Therapy

One subgroup of SAD patients and healthy controls respectively will receive bright light therapy using an artificial white light source (PhysioLight LD220 by DAVITA®, www.davita.de/shop/lichttherapiegeraete/lichtduschen-tageslicht/physiolight-ld-220.html) with full-spectrum 10.000lux light intensity. The treatment will be applied 30min per day at a distance of about of 50cm, preferably in the morning, during 3 weeks.

Group Type EXPERIMENTAL

Light Therapy

Intervention Type OTHER

One subgroup of SAD patients and healthy controls respectively will receive bright light therapy using an artificial white light source (PhysioLight LD220 by DAVITA®, www.davita.de/shop/lichttherapiegeraete/lichtduschen-tageslicht/physiolight-ld-220.html) with full-spectrum 10.000lux light intensity. The treatment will be applied 30min per day at a distance of about of 50cm, preferably in the morning, during 3 weeks.

Placebo Light

The second subgroup of the SAD patients and healthy controls will receive a non-biologically active light source (\<400nm or \>500nm). Here, the lamp will have largely similar shape and size as compared to the therapeutic device, but the fluorescent tube with the high light intensity will be replaced by an ordinary bulb.

Group Type PLACEBO_COMPARATOR

Placebo Light

Intervention Type OTHER

The second subgroup of the SAD patients and healthy controls will receive a non-biologically active light source (\<400nm or \>500nm). Here, the lamp will have largely similar shape and size as compared to the therapeutic device, but the fluorescent tube with the high light intensity will be replaced by an ordinary bulb.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Light Therapy

One subgroup of SAD patients and healthy controls respectively will receive bright light therapy using an artificial white light source (PhysioLight LD220 by DAVITA®, www.davita.de/shop/lichttherapiegeraete/lichtduschen-tageslicht/physiolight-ld-220.html) with full-spectrum 10.000lux light intensity. The treatment will be applied 30min per day at a distance of about of 50cm, preferably in the morning, during 3 weeks.

Intervention Type OTHER

Placebo Light

The second subgroup of the SAD patients and healthy controls will receive a non-biologically active light source (\<400nm or \>500nm). Here, the lamp will have largely similar shape and size as compared to the therapeutic device, but the fluorescent tube with the high light intensity will be replaced by an ordinary bulb.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* DSM-IV diagnosis of SAD established by diagnostic interview according to the SCID.
* Global Seasonality Score of 10 or higher on the Seasonal Pattern Assessment Questionnaire (SPAQ)
* Somatic health based on history, physical examination, ECG, and laboratory screening
* Aged 18 to 55 years
* No therapeutic treatment of SAD in the last 6 months (drugs and light therapy)
* Willingness and competence to complete the informed consent process

* Aged 18 to 55 years
* Somatic and psychiatric health based on history, physical examination, ECG, laboratory screening, SCID
* Willingness and competence to complete the informed consent process

Exclusion Criteria

* Concomitant major medical or neurological illness
* Concomitant psychiatric disorders
* Current smoking
* Ingestion of antidepressants or other psychotropic agents targeting the serotonergic system, within the last 6 months.
* Bright light therapy within the last 6 months.
* Current substance abuse including alcohol, drugs of abuse, or any medication in a manner which is indicative of substance-related disorders (e.g. substance dependency) according to the DSM-IV.
* Failure to comply with the study protocol or follow the instructions of the investigators.
* Positive urine pregnancy test.
* For participants who participated in an earlier neuroimaging study using ionizing radiation, the total radiation exposure dose of 20 mSv over the last 10 years must not be exceeded, as specified in the legislation on radiation protection (Allg. Strahlenschutzverordnung 2010; www.ris.bka.gv.at).

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes